IL-6R blockade by chikusetsusaponin IVa butyl ester inhibits Th17 cell differentiation and ameliorates collagen-induced arthritis
- 26 February 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 18 (6), 1584-1586
- https://doi.org/10.1038/s41423-021-00651-6
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81773973)
This publication has 7 references indexed in Scilit:
- Translating IL-6 biology into effective treatmentsNature Reviews Rheumatology, 2020
- Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2019
- Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trialThe Lancet, 2016
- Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell ApoptosisMolecular Cancer Therapeutics, 2016
- Brief Report: Inhibition of interleukin‐6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritisArthritis & Rheumatism, 2012
- IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patientsImmunology Letters, 2010
- Interleukin‐6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responsesArthritis & Rheumatism, 2008